NSAV Holding Inc (NSAV)

[al19]

NSAV NEWS NSAV NEWS

ANGRY TIGER BEER, FIRST HEMP BEER BEING BOTTLED IN CHINA !!! HUGE

NSAV HOLDING COMPANY IS MAKING HUGE DEALS , READ BELOW AND DD.

lOADING ZONE !!!



I understand that an NSAV shareholder received an email from German blockchain/ICO giant, Draglet https://www.draglet.com , confirming that Draglet is an adviser to our ICO and blockchain and will be listed in our latest version of the Whitepaper as an adviser. Huge for MJCoin.

NSAV Holding, Inc.
?

@NSAV_MJTechCo
Feb 27
More
The appointment of Draglet as an adviser to MJCoin and being included in the Whitepaper will be in a PR asap. Don't worry about that.
Nsav Announces Medtronic Partnership With Heart Rescue ProjectPress Release | 02/15/2018
Cresco, PA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that Medtronic PLC ( www.medtronic.com ) will be the lead sponsor and partner of the Company’s Heart Rescue Project. The project is headed by the Company’s subsidiary, Shanghai based Vital Strategic Research Institute (VSRI) and Shanghai Jiao Tong University (SJTU) School of Medicine. The project aims to improve access and quality for acute Cardio Vascular Disease (CVD) care in China, where over 200 million Chinese suffer from the world’s leading cause of death. Medtronic is among the world's largest medical equipment development companies and employs over 85,000 people. In 2017 Medtronic posted revenues US$ 29.71 billion and a net income of US$ 4.02 billion. For more information, please visit the project websites below

NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANYPress Release | 12/21/2017
December 21, 2017
OTC Disclosure & News Service

Cresco, PA —

This release includes additional documents. Select the link(s) below to view.
NSAV-VSRI-Eli Lilly Agreement Part 1.PDF
NSAV-VSRI-Eli Lilly Agreement Part 2.PDF
Net Savings Link, Inc. (OTC:NSAV) -- a medical technology and software company, announced today that its subsidiary, Shanghai based Vital Strategic Research Institute (VSRI), has signed an agreement with Eli Lilly and Company. Under the terms of the agreement, VSRI will provide Eli Lilly with an assessment of Cardio Vascular Disease (CVD) among newly diagnosed diabetes patients at increased risk of CVD in China. China is facing the largest diabetes epidemic in the world with around 11 percent of its population suffering from the metabolic illness, while nearly 36 percent are pre-diabetic. CVD in China has also reached epidemic proportions, with over 200 million Chinese suffering from the worlds leading cause of death.

About Eli Lilly and Company

Eli Lilly and Company, a leading innovation-driven company, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at www.lilly.com.

NSAV subsidiary, VSRI is a medical research firm with a long history of expertise in design, clinical trials and global research. VSRI has collaborated with pharmaceutical giants such as Pfizer and Bristol-Myers Squibb.